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Summary
Four agents — acarbose (ACA), 17-a-estradiol (EST), nord-
ihydroguaiaretic acid (NDGA), and methylene blue (MB) — were
evaluated for lifespan effects in genetically heterogeneous mice
tested at three sites. Acarbose increased male median lifespan by
22% (P < 0.0001), but increased female median lifespan by only
5% (P = 0.01). This sexual dimorphism in ACA lifespan effect
could not be explained by differences in effects on weight.
Maximum lifespan (90th percentile) increased 11% (P < 0.001) in
males and 9% (P = 0.001) in females. EST increased male median
lifespan by 12% (P = 0.002), but did not lead to a significant
effect on maximum lifespan. The benefits of EST were much
stronger at one test site than at the other two and were not
explained by effects on body weight. EST did not alter female
lifespan. NDGA increased male median lifespan by 8–10% at
three different doses, with P-values ranging from 0.04 to 0.005.
Females did not show a lifespan benefit from NDGA, even at a
dose that produced blood levels similar to those in males, which
did show a strong lifespan benefit. MB did not alter median
lifespan of males or females, but did produce a small, statistically
significant (6%, P = 0.004) increase in female maximum lifespan.
These results provide new pharmacological models for exploring
processes that regulate the timing of aging and late-life diseases,
and in particular for testing hypotheses about sexual dimorphism
in aging and health.
Key words: acarbose; estradiol; heterogeneous mice; life-
span; methylene blue; NDGA.
Introduction
Interventions that improve mammalian lifespan may provide new insights
into the physiological factors thatmodulate aging rate andmay eventually
lead to treatments useful in the clinic to improve human health with age.
Interventions that improve lifespan also are important for basic research,
because different models of delayed aging can be contrasted to
distinguish what biological effects are essential in delaying aging.
The National Institute on Aging Interventions Testing Program (ITP)
has previously reported significant increases in lifespan caused by aspirin
and nordihydroguaiaretic acid (NDGA) in male mice (Strong et al., 2008)
and by rapamycin in both male and female mice (Harrison et al., 2009;
Miller et al., 2011; Wilkinson et al., 2012). The design of the ITP,
presented at this URL: (http://www.nia.nih.gov/research/dab/interven-
tions-testing-program-itp), uses genetically heterogeneous (UM-HET3)
mice, the offspring of the CByB6F1 x C3D2F1 cross. This cross produces
a broad set of genetically diverse individuals, thus minimizing the
possibility that characteristics of a single inbred or F1 hybrid genotype
might be confused with those of the species. The ITP includes parallel
replication of protocols at three sites, the University of Texas Health
Science Center at San Antonio (UT), University of Michigan (UM), and
The Jackson Laboratory (TJL), using standard operating protocols that
reproduce key elements of the environmental conditions at each site.
Sufficient numbers of mice are used in each yearly cohort to give more
than 80% power to detect an increase or decrease of 10% in mean
lifespan, with respect to controls of the same sex, even if only two of the
three sites can contribute data to the pooled analysis.
The interventions for this study were chosen for the following
reasons:
● Acarbose (ACA) is a plausible calorie restriction mimetic. Archer
(2003) suggests that the postmeal spike in glucose may contribute
to aging. This spike is reduced by ACA (Balfour & McTavish, 1993).
Acarbose has been used clinically to prevent postprandial hyper-
glycemia for many years, and there are several reports showing its
ability to limit or prevent postprandial hyperglycemia in mice as
well (Frantz et al., 2005; Kim et al., 2011; Miyamura et al., 2010).
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The glucose spike during a meal is blunted because acarbose
inhibits a-glucosidases in the intestine, thereby slowing the
digestion of starches and disaccharides to glucose. Acarbose does
not sequester glucose, nor block its uptake—it blocks its release
from complex polysaccharides. Like diet restriction (DR), chronic
ACA treatment reduces body weight and body fat, and also
improves glucose dysregulation associated with aging (Yamamoto
& Otsuki, 2006). DR greatly increases lifespan of both male and
female UM-HET3 mice, the cross used in the current study (Flurkey
et al., 2010). Unlike DR, food intake is often increased, not
reduced, during long-term ACA treatment (Yamamoto & Otsuki,
2006).
● 17-a-estradiol (EST) is considered to be a nonfeminizing estrogen
with reduced affinity for estrogen receptors. This estrogen is
neuroprotective against ischemia in animal models, as well as
in vitro (Perez et al., 2005). It also protects against neurodegen-
erative effects in cell and animal models of Parkinson’s disease
(Dykens et al., 2005) and cerebrovascular disease (Liu et al., 2005).
In general, nonfeminizing estrogens should not cause the kinds of
deleterious effects seen in chronic estrogen therapy. Also, 17-a-
estradiol should mimic the effects of 17-b-estradiol, particularly on
neural tissues that are independent of the classical estrogen
receptors. Studies in other laboratories, in mice and in neuroen-
docrine cell lines, have suggested that some of the effects of 17-b-
estradiol, particularly with respect to its CNS effects, may be due to
actions independent of the classical estrogen receptor (Huggins
et al., 1954; Korenman, 1969; Kneifel et al., 1982; Green et al.,
1997). We hypothesized that 17-a-estradiol might mimic these
receptor-independent effects and lead to health benefits in male
mice.
● Methylene blue (MB) greatly increases in vitro fibroblast lifespan
and increases activity of mitochondria complex IV (Atamna et al.,
2008). It also protects against seizures and oxidative damage in rat
brain (Furian et al., 2007), as well as protecting against radiation, a
standard cause of oxidative damage (Chung & Nam, 1975).
● Nordihydroguaiaretic acid (NDGA; also called masoprocol) has
both antioxidant and anti-inflammatory properties (Zhang et al.,
2013). In a previous study, the ITP researchers showed that NDGA
increases median lifespan in males but not females. This sexual
difference was tentatively attributed to differences in NDGA
pharmacodynamics, because NDGA levels in serum were much
higher in males than in females (Strong et al., 2008). Thus, in this
current study, we evaluated a range of concentrations in males and
tested whether a higher dose of NDGA would increase blood levels
and improve lifespan in females.
Results
Effects of treatments on lifespan and markers of aging
Acarbose
Mice were fed ACA at 1000 mg kg1 diet (1000 ppm) from 4 months
of age. Male median lifespan was increased by 22% (P < 0.0001) and
female median lifespan by only 5% (P = 0.01) (Fig. 1), using data pooled
across sites. Figure 2 shows site-specific survival curves for both sexes. In
male mice fed ACA (Fig. 2A–C), median lifespan was increased as
follows: TJL (21%, 807–974 days, P = 0.0003); UM (8%, 925–999 days,
P = 0.054); and UT (39%, 704–981 days, P < 0.0001). In sharp
contrast, survival was affected far less in females fed ACA (Fig. 2D–F),
with no significant effect at TJL (decreased from 918 to 911 days) or UM
(increased from 887 to 949 days) and with a barely significant increase
at UT (7%, 864–942 days, P = 0.04). Analyses of pooled and site-
specific data are summarized in Table 1.
Unlike survival curves and median lifespan, maximum lifespan
(measured as the 90th percentile) in pooled data was increased to a
similar degree in males and females; ACA caused an increase of 11%
(P < 0.001) for males and 9% (P = 0.001) for females (Table 1). Giving
site-specific data, in male mice fed ACA, maximum lifespan increased
14% at TJL, 6% at UM, and 19% at UT. Maximum lifespan in females
fed ACA increased 6% at TJL, 6% at UM, and 10% at UT (Table 1). At
TJL, there were many early deaths in females, but preferential survival for
ACA in the oldest female mice. For UT females, results of the log-rank
test were significant, but there was no significant effect on the late-life
survival. For UM females, the trend was similar to that seen at UT, but
the effect was less dramatic than at UT.
Interestingly, while survival of control UM-HET3 males was shorter at
TJL and UT than at UM (P < 0.001; Fig. S1A), survival of ACA males
increased most dramatically at TJL and UT, so that survival of ACA males
did not differ among sites (P > 0.5; Fig. S1C). Survival of control UM-
HET3 females did not differ among sites (P > 0.3; Fig. S1B) and also did
not differ with ACA (P > 0.6; Fig. S1D).
In a separate group ofmice, not involved in the lifespan study, ACAwas
administered from 4 months of age, and several physiological indices
were evaluated over the next 8 months (Fig. 3). Hemoglobin A1c (HbA1c)
was used as an integrated measure of blood glucose levels over the
previous 6 weeks and showed no effects of sex or of ACA (Fig. 3A).
Fasting blood glucose levels were higher in ACA-fed males (P = 0.048)
and females (P ≤ 0.0001) (Fig. 3B), consistent with the idea that ACAmay
delay the digestion of complex carbohydrates and absorption of sugars
from the gastrointestinal tract. FGF21, a hormone produced by liver in
response to fasting, extends lifespan when over-expressed in B6 mice
(Zhang et al., 2012). Plasma FGF21 levels, measured in the morning after
overnight fasting in 9-month-old mice, were elevated by ACA, but were
greatly reduced by DR (Fig. 3C), showing a major difference in effects of
ACA compared with DR. Figure 3D shows that IGF1 levels in plasma were
significantly reduced by ACA in UM-HET3 males (P = 0.02) and females
(P = 0.0001). Figure 3E shows that ACA reduced fasting insulin signifi-
cantly in males (P < 0.001) but not in females (P = 0.6). The age-
associated decline in voluntary activity from 5 to 11 months was reduced
in females (P = 0.007) by ACA feeding, but was not affected in males. DR
mice showed an increase in activity in these young adultmice of both sexes
(Fig. 3F), showing another difference between effects of ACA and DR.
Acarbose reduced body weights considerably more in females than in
males: At 6, 12, 18, and 24 months of age, males were 15%, 14%,
11%, and 9% lighter than controls, while females were 15%, 22%,
23%, and 22% lighter, respectively (Fig. 4). Only pooled data are shown
in the figure; data from each site were similar (Fig. S2). In all cases, loss of
weight due to ACA was as high or higher in females than in males.
17-a-estradiol (EST)
One group of mice was fed 4.8 mg EST/kg diet from 10 months of age.
In males fed EST, median lifespan increased only 3% at TJL and at UM
(not significant), but at UT, lifespan increased 28%, (P = 0.0008;
Fig. 5B–D; Table 1). Pooled median lifespan increased 12% (P = 0.0012;
Fig. 5A), clearly due to the very strong benefits on male lifespan from
EST at UT (Fig. 5D). There was no significant effect on maximum lifespan
in males. EST feeding had no significant effect on female survival either
in the pooled data or at any individual site (Table 1; Fig. S3). At 12, 18,
and 24 months of age, males fed EST were 11%, 10%, and 8% lighter
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than controls (Fig. 4A), while females fed EST were 6%, 7%, and 7%
lighter than controls (Fig. 4B).
Although EST is considered to be nonfeminizing, there is evidence
that it has similar affinity for estrogen receptors a and b (Toran-Allerand
et al., 2005) and can have uterotrophic effects (Clark et al., 1982). We
therefore tested for feminizing activity of the EST diet in a separate
population of young ovariectomized UM-HET3 mice at UT. EST fed to
ovariectomized mice for 6 weeks did not increase uterine weight or
cause cornification of the vaginal epithelium, indicating that at the dose
used in this study, EST had no detectable bioactivity in the female
reproductive tract.
Nordihydroguaiaretic acid (NDGA)
Starting at 6 months of age, male UM-HET3 mice were fed NDGA at
three different doses, 800, 2500, or 5000 mg kg1 diet (referred to as
low, middle, or high-dose NDGA). Median survival of males was
increased significantly at each of the three doses, as evaluated using
the log-rank test. Estimates of the 90th percentile survival and statistical
tests of maximum lifespan are not yet available from this cohort of mice.
The middle dose led to increased male lifespan in a prior study (Strong
et al., 2008) and is replicated in our current independent cohort.
Figure 6A shows male interim survival curves pooled from all three sites.
At the time of writing, about 30% of the cohort is still alive, and the
youngest mice are approximately 850 days old; thus, the exact shapes of
the survival curves shown in Fig. 6 are not defined above 850 days. In
data pooled across sites, median lifespan for male controls was 787 days
and was increased to 851 (P = 0.04), 868 (P = 0.0053), and 860
(P = 0.0048) days in groups fed low, middle and high doses of NDGA.
NDGA was fed to females only at the high dose, 5000 mg kg1, and
female survival curves, about 70% complete, were not affected
(Fig. 6B), with control and high-dose NDGA median lifespan 897 and
880 days, respectively. This is consistent with our previous study, in
which female lifespan was not affected by NDGA at 2500 mg kg1, the
middle dose in males in the current study. Interim survivals at the three
sites are similar (Fig. S4), except that the high dose may reduce longevity
slightly at UM while the high dose is the best of the three at increasing
survival at TJL and UT. As in the previous cohort, survival of male controls
at TJL and UT is much shorter than at UM in the current cohort of mice.
(A) (B)
Fig. 1 Survival curves comparing controls
and mice fed Acarbose (ACA) for males (A)
and females (B) pooled across the three
sites. On this and other figures here,
significance of differences between control
and test mice are given as ‘P’ values on
each set of curves.
(A) (B) (C)
(D) (E) (F)
Fig. 2 Survival curves comparing controls and mice fed Acarbose (ACA) for males (A,B,C) and females (D,E,F) from each of the three sites: TJL (A,D), UM (B,E), and UT (C,F).
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Starting at 6 months of age, a cohort of male and female UM-HET3
mice at each site were fed diets containing different concentrations of
NDGA. At 23–25 months of age, the mice were bled and the samples
sent to the UT site for measurement of NDGA blood levels. Whole blood
NDGA was proportional to the dose fed male mice: 140, 55, and
25 ng mL1 plasma at the high, middle, and low dose, respectively. In
female mice fed the high dose, the plasma concentration of NDGA was
60 ng mL1, similar to that in males fed the middle dose (Fig. S5).
Methylene blue (MB)
Starting at 4 months of age, UM-HET3 mice were fed 27 mg MB per kg
diet. Survival curves for pooled male or female data were not changed
significantly by MB (Fig. 5E,F). Male survival was not affected at any of
the three sites, although there was a suggestion (P = 0.07) of a negative
effect at TJL, with a 13% decline in median survival.
Female median survival was not affected at TJL or UT; median lifespan
increased 12% (P = 0.048) at UM (Table 1, Fig. S7). While statistically
significant, we do not consider this of biological significance, especially
because the effect of MB in female data pooled from the three sites is
only a nonsignificant 1% increase in lifespan (Fig. 5F). However,
maximum lifespan was increased at both TJL and UM, so a 6% increase
in females using pooled data (90th percentile age of 1072 in controls
and 1138 days in MB females) was significant (P = 0.004; Table 1).
Effects of treatments on lesions and inferred causes of death
Table S1 summarizes numbers of different lesions that are inferred
causes of death. Of the 128 cases for which the pathologist could infer a
single specific cause of death, there were no significant differences
between control and ACA-treated mice or between control and EST-
treated mice in the proportion of mice dying with any cause of death,
probably because so many different causes are represented. In addition
to specifying a likely cause of death, the pathologist also evaluated the
severity of age-related ‘incidental’ lesions, that is, lesions that did not
lead to death. In this analysis, the incidence of liver degeneration was
reduced by ACA from 42% to 3% (P = 0.001) in males, but ACA did not
have a similar effect in females, with 17% liver degeneration in ACA-
treated and 13% in controls. It is possible that improved liver function in
ACA-treated males may have contributed, in unknown ways, to their
improved survival. ACA increased the incidence of cold thyroid follicles
(from 78% to 92%, P = 0.05) with no effect of sex. This significance
level is borderline in a series of multiple comparisons. Hepatic lipidosis
Table 1 Summary of survival curve information for ACA-, EST-, and MB-treated mice in Cohort 2009, in which all mice have died
Median lifespan Age at which 90% have died
Control
mice (days)
Treated
mice (days) Difference (%)
Log-rank,
P value
Control
mice (days)
Treated
mice (days)
Wang-Allison,
P value
ACA: Males
Pooled 807 984 22 <0.0001 1094 1215 <0.001
TJL 807 974 21 0.0003 1061 1212 0.09
UM 925 999 8 0.054 1051 1219 0.04
UT 704 981 39 <0.0001 1013 1204 <0.001
ACA: Females
Pooled 896 939 5 0.0101 1072 1167 0.001
TJL 918 911 1 0.4 1084 1148 0.01
UM 887 949 7 0.13 1089 1152 0.14
UT 864 942 9 0.04 1062 1167 0.11
EST: Males
Pooled 807 900 12 0.002 1094 1148 0.13
TJL 807 828 3 0.6 1061 1117 0.8
UM 925 949 3 0.18 1151 1187 0.4
UT 704 900 28 0.0008 1013 1110 0.2
EST: Females
Pooled 896 893 0 0.8 1072 1068 0.9
TJL 918 867 6 0.9 1084 1107 0.5
UM 887 910 3 0.3 1089 1006 0.2
UT 864 903 5 0.6 1062 1079 0.4
MB: Males
Pooled 807 790 2 0.27 1094 1037 0.6
TJL 807 701 13 0.07 1061 1009 0.2
UM 925 905 2 0.96 1151 1157 0.8
UT 704 699 1 0.9 1013 980 0.9
MB: Females
Pooled 896 902 1 0.17 1072 1138 0.004
TJL 918 862 6 0.9 1084 1121 0.2
UM 887 993 12 0.048 1089 1159 0.01
UT 864 880 2 0.8 1062 1075 0.4
Pooled data represent all mice without adjustment for numbers at each site. The individual site values (TJL, UM, UT) are given below the pooled values. Medians of controls
are repeated for comparison with medians of treated mice. Log-rank P-values consider all the data, while the Wang–Allison test evaluates the proportion of live mice in
control and treatment groups at the age in days at which 90% of the ice have died.
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(‘macro lipidosis’) is diminished significantly by ACA (from 27% to 4%,
P = 0.002) in the pooled data. In males, ACA reduces this finding,
P = 0.02, while the incidence is so low in control females that the ACA
effect is not significant. EST has a similar effect, with a reduction from
27% to 6% (P = 0.006) in pooled data, and P = 0.01 in males alone, but
there is no significant effect in females. Because this type of lesion is
more common in males than in females, its reduction also may help
explain the unbalanced benefits of ACA and EST on male survival.
Overall patterns did not change when early deaths were
removed
Due to significant early deaths in males at UT and TJL, probably related
to mouse urinary syndrome (MUS) (Tuffery, 1966; Everitt et al., 1988),
male survival statistics were recalculated after eliminating all deaths at
ages earlier than 600 days, to estimate survival effects in those mice that
reach at least 600 days, ~ 20 months of life (Table S2). Overall, the
findings were similar to those in males with all deaths considered:
significant positive effects of ACA and EST, but not MB. Exclusion of
males dying before 600 days reduces the percentage effect of ACA
(from 22% to 13%) and EST (from 12% to 5%), but the log-rank tests
are significant even with lower values of N. In these left-censored data
sets, ACA had a significant benefit at TJL and UT, with a similar nearly
significant pattern (P = 0.055) at UM. In the truncated data sets taken at
individual sites, EST had a significant benefit only at UT, similar to the
findings with the complete data sets shown earlier.
Discussion
Interventions that increase lifespan may be doing so by retarding aging
and, thus, may provide powerful tools for analyzing the biology of aging
and late-life diseases. Data showing that a drug can increase lifespan are
the first step in developing the case that the drug can delay or decelerate
aging. Repeatable evidence that mouse lifespan can be extended by
drugs has developed only recently (Strong et al., 2008; Harrison et al.,
2009; Miller et al., 2011), and the question of whether these lifespan
effects do indeed reflect slower aging is under active investigation (Chen
et al., 2009; Wilkinson et al., 2012). Here, we report strong evidence for
lifespan extension by ACA, evidence for a possible effect of EST, and
strong confirmatory evidence for benefits from NDGA. Surprisingly, each
of these three agents extends lifespan either in males only or (for ACA)
much more strongly in males than in females. These data thus provide
new systems for exploring questions about sex-specific processes that
regulate lifespan and late-life illnesses.
Lifespan studies provide a valuable screening tool to identify agents
(e.g., drugs or diets) that might slow aging and thereby delay the onset
(A) (B)
Fig. 4 Weights are given for males (A) and females (B) at 6-month intervals for
controls and mice fed Acarbose (ACA), EST, and MB. Data were pooled from the
three sites.
(A) (B) (C)
(D) (E) (F)
Fig. 3 Data from an independent group of
mice fed the standard Acarbose (ACA) diet
starting at 4 months of age, tested at UM
only. (A–E) Results from blood tests at
9 months of age: HbA1c, fasting glucose,
FGF21, IGF1, and fasting insulin. (F)
Activity, scored at 11 months as the
number of beam interruptions in 50 h,
adjusted for each mouse as a change score
with reference to activity at 5 months for
the same mouse. Diet restriction (C,F) was
started at 4 months; mice were fed 60% of
their normal consumption after a 2-week
transitional period at 80%. Each bar shows
mean and standard error of the mean.
Numbers of mice: (A,B,D,E) n = 17–20 of
each sex; (C) n = 10 per group, sexes
pooled because there was no sex
difference; (F) n = 17–18 males, 20
females.
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of the wide range of age-related diseases, including those that lead to
death. It is, however, a realistic possibility that an agent might extend
lifespan by an effect on a specific kind of lethal illness, such as the
neoplastic diseases that are the usual cause of death in laboratory mouse
stocks. Further work on a range of age-sensitive changes, in many cells
and tissues, are needed to determine whether NDGA, ACA, or EST are
extending longevity by retarding basic mechanisms of aging, by
postponing death from multiple forms of neoplasia, or by a combination
of these. The ITP protocol uses genetically heterogeneous mice to
minimize the risk of confusion due to unique characteristics of single
inbred or isogenic genotypes. Further studies of ACA, EST, and NDGA in
a wide variety of mouse stocks will be of high interest, to identify
pathways and genetic contributors to the lifespan extension effects.
One possible reason for the larger or exclusive effects of these
compounds on males is the short lifespan of the male controls at two of
the three sites (medians of 704, 807, and 924 days from male controls at
UT, TJL, and UM, respectively, while female control medians are 864,
918, and 887, Table 1). As in all previous ITP cohorts (Strong et al.,
2008; Harrison et al., 2009; Miller et al., 2011), unknown site-specific
differences lead to male control mice living longer at UM than at UT and
TJL, without producing corresponding discrepancies among female
controls. We do not know why this occurs, and we do not know
whether the factors that distinguish TJL from UM males are the same as
those that distinguish UT from UM males. If we knew the basis for the
site-specific effect on control lifespan, and why it affects only males, we
would be able to test the idea that the stronger (proportional) response
of males to interventions such as ACA at TJL and UT represented a
correction of the postulated sex-and-site-specific factor(s). We cannot
rule this idea out, but we also cannot test it without a plausible
hypothesis as to the nature of the factor(s) involved. The data at hand
suggest that the situation may be complex and not attributable to a
single factor.
Acarbose (ACA). We expected ACA to mimic many effects of diet
restriction (DR). The diet used in these studies, Purina 5LG6 diet, has
(A) (B)
Fig. 6 Survival curves comparing male
controls and male mice fed NDGA at three
different doses (A). Data for female controls
and female mice fed the high dose of
NDGA (B). Data were pooled from the three
sites.
(A) (B) (C)
(D) (E) (F)
Fig. 5 Survival curves comparing controls and mice fed EST for males pooled from the three sites (A) and for males at each site: TJL (B), UM (C), and UT (D). Survival curves
for males and females fed MB pooled from the three sites are (E) and (F), respectively.
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high starch and low sucrose. We expected that ACA, by slowing
complex carbohydrate digestion, might limit absorption of sugars and
simple carbohydrates, thus leading to lower overall caloric intake and
producing effects similar to those of DR. DR at 2/3 normal food
consumption started at 4–5 weeks of age increased survival of UM-
HET3 mice, with mean lifespan increasing 40% (836–1169 days) in
females and 32.5% (831–1101 days) in males; DR decreased body
weight to about half in both sexes (Flurkey et al., 2010). Thus, we
expected that ACA might produce some survival benefits, although not
as much as produced by DR, because the weight reductions from ACA
(Fig. 4) were much less than those seen in DR mice. In addition, as
weight reductions (% body weight) due to ACA were greater in
females than in males (Fig. 4), we hypothesized that lifespan effects
would, similarly, be larger in females. The results were thus surprising:
median lifespan was increased 22% in males and only 5% in females
(Fig. 1).
The fact that female control lifespans do not differ at the three sites,
but are still increased significantly by ACA, suggests that ACA may affect
basic mechanisms of aging that affect survival in both sexes. In addition,
it is noteworthy that the effects of ACA in male mice at UM, where male
controls are longest-lived, approached or met conventional criteria for
statistical significance (P = 0.054 for log-rank test; P = 0.04 for Wang/
Allison test of 90th percentile survival) despite the limited statistical
power at any single test site. The idea that ACA has effects on aging and
survival independent of site-specific environmental factors is further
supported by the fact that in both males and females, maximum lifespan
(90th percentile) is increased significantly and similarly in the pooled data
for both males (11%, P < 0.001) and females (9%, P = 0.001) (Table 1).
Maximum lifespan often indicates effects on mechanisms of aging more
reliably than mean or median lifespan, as the latter may be altered by
early deaths unrelated to aging.
Acarbose reduced weight more in females than in males (Fig. 4).
Thus, the lengthened survival for ACA-treated males vs. ACA-treated
females cannot be explained by changes in body weight or seen simply
as the effect of overall caloric restriction. It is not currently known
whether slower weight gain is a direct effect of loss of caloric content
absorbed or represents a modulation of CNS and gastrointestinal
endocrine circuits, perhaps with modification of appetite and associated
metabolic set points. The data in Fig. 3 provide an initial indication of key
physiological parameters in young adult ACA-treated mice. The lower
fasting glucose values, in combination with the unaltered HbA1c levels,
are consistent with the idea that ACA may diminish the amplitude of
postprandial spikes in plasma glucose levels, with lower peak levels but
higher trough levels in both sexes. In both blood levels of FGF21 and
activity, effects of ACA differed from effects of DR (Fig 3C,F), and thus
benefits of ACA on lifespan may not be attributed simply to diminished
caloric intake. The male-specific decline in fasting insulin level hints that
this altered diurnal pattern of glucose spikes may produce higher insulin
sensitivity in males, with less effect in females, which might in turn
contribute to the sexual dimorphism in longevity effect. Furthermore,
differences between ACA and CR may be due to carbohydrate vs. total
diet restriction or to changes in the microbiome. Each of these ideas
warrants more thorough evaluation at different ages and in different
tissues involved in glucose homeostasis. ACA-treated mice also had a
mild reduction in plasma IGF1 levels, of equivalent size in both sexes.
Yuan et al. (2012) showed a strong association among mouse strains
between levels of IGF1 at 6 months of age and lifespan, but this
association disappeared when IGF1 was tested at 12 and 18 months of
age. There is some evidence that IGF1 levels at 6 months may predict
lifespan in F1 hybrids (Harper et al., 2006) as well as in UM-HET3 mice,
where low levels at 15 months predicted increased lifespan (Harper
et al., 2003).
17 a-estradiol (EST) was suggested as an anti-aging intervention on
the grounds that it might mimic, in male mice, the beneficial effects
produced by estrogen in control females and might avoid the serious
adverse effects of chronic estrogen treatment mediated by activation of
estrogen receptors. Thus, rather than using hormonally active estrogen,
we used a nonfeminizing estrogen with reduced binding for estrogen
receptors. This class of nonfeminizing estrogen has shown many health
benefits (Dykens et al., 2005; Liu et al., 2005; Perez et al., 2005), and
non-feminizing estrogens should not cause deleterious effects seen in
chronic estrogen therapy (Wang et al., 2006). EST feeding was started at
10 months of age in mice, at the age when estrus cycling and
reproduction begin to slow down in long-lived females (Nelson et al.,
1982). Evidence for effects on aging was inconclusive. EST feeding had
no effect on lifespan in females, as expected. Although the pooled data
showed a significant longevity benefit in males, the magnitude of this
effect was far stronger at UT than at the other two test sites (Table 1,
Fig. 5). Interestingly, weights were affected by EST to a similar degree at
TJL and UT (Fig. S2), although a large increase in survival only occurred at
UT. Thus, the reduction in weight in males does not consistently explain
the great effect of EST on male survival at UT. The test of the hypothesis
that 17-a-estradiol might improve health in males thus gives equivocal
results—a dramatic benefit in males at one site but no significant
benefits at the other two sites. More work will be needed to see whether
or not the EST result is a site-specific observation. If the health benefits
males at UT are replicated, perhaps by other groups, on other stocks, or
at higher doses of 17-a-estradiol, this should motivate follow-up studies
to learn which cell type(s) and which estrogen-dependent/independent
events are responsible for the benefit.
Nordihydroguaiaretic acid (NDGA) has been shown in a previous
cohort to increase lifespan in male but not female UM-HET 3 mice
(Strong et al., 2008). We tested it a second time because NDGA serum
concentrations were, in the original study using 2500 ppm NDGA, much
lower in females than in males, which might explain the absence of
lifespan benefit in females. In the current study, we evaluated a higher
dose of NDGA (5000 ppm) in an attempt to increase blood levels to see
whether these would increase female lifespan. The blood level was
indeed increased in females receiving 5000 ppm to a value similar to
that in males receiving 2500 ppm NDGA (Fig. S5), but we saw no
evidence for an increase in female lifespan with 70% of the survival
curve complete (Fig. 6). Effects in males (Fig. 6) were similar to those
reported in our earlier study (Strong et al., 2008), and the medium dose
of NDGA used previously was the most consistent at increasing lifespan
(Figs. 6 and S4). The new data confirm the original report in an
independent cohort, show that the lack of effect in females is not due
simply to altered pharmacodynamics, and provide helpful information on
the dose–response relationship. Although the current NDGA survival
experiment is not complete, it is apparent that NDGA, such as ACA and
EST, has a significant benefit in males but not in females. In males, the
low and middle doses did not affect body weight, but the high dose
caused a small reduction (Fig. S6). The high dose reduced female body
weight about 14%, 22%, and 23% at 12, 18, and 24 months,
respectively, while male weight was only reduced 3–6% (Fig. S6B); thus,
the lack of effect of NDGA on female lifespan cannot be explained by
concentration in the plasma or by effects on body weight. It is possible
that NDGA produces beneficial effects in both sexes but produces
harmful effects in females that prevent lifespan extension. Further data,
in both sexes, on age-dependent changes, including those related to
overall health, will be needed to determine whether NDGA modulates
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multiple aspects of aging in either or both sexes. It is noteworthy that
several of the agents found to extend lifespan in the ITP series, that is,
aspirin, NDGA, and rapamycin, inhibit some forms of inflammatory
response, consistent with suggestions that late-life inflammation is an
important aging process (Jenny, 2012). A mutation that blocks produc-
tion of the pro-inflammatory cytokine MIF (migration inhibition factor)
also extends mouse lifespan (Harper et al., 2010).
Methylene blue (MB) extends proliferative lifespan of human embry-
onic fibroblasts (IMR90) and also increases the activity of mitochondrial
complex IV as well as mitochondrial heme synthesis in these fibroblasts;
it reverses accelerated senescence in vitro due to oxidative stress and
induces antioxidant defense enzymes in HepG2 cells (Atamna et al.,
2008). Despite this, and the protection against irradiation, brain
damage, poisoning, and chemotherapy in vitro, MB did not lead to
strong or consistent effects on lifespan in UM-HET 3 mice at the dose
used, although it did lead to a statistically significant improvement in
female maximum lifespan (Fig. 5F), as measured by the proportion of
surviving mice at the 90th percentile age in the pooled data set. Specific
effects on median lifespan at a single site suggest damage in males (TJL)
or benefits in females (UM), but these effects disappear in pooled data
(Table 1). There is a 6% increase in female maximum 90% lifespan that
is significant (Table 1). However, because the effect is so small, and
limited to one sex, the data fail to support the hypothesis that MB is an
effective anti-aging intervention at the dose used.
We evaluated slope and intercept of the Gompertz distribution for
males and females exposed to EST, ACA, and MB as previously described
(Miller et al., 2011). For females, pooling across sites, there were no
significant effects of any of these agents on the slope or intercept
coefficients. For males exposed to ACA, slope is increased and intercept
is decreased, although interpretation of these effects is complicated by
the high sensitivity of both parameters to early deaths whose relation-
ship to aging processes is obscure. Neither MB nor EST led to a
significant alteration in either Gompertz parameter.
We believe our new data provide several important steps toward the
understanding of aging mechanisms and the search for clinical strategies
to retard chronic diseases. ACA represents the second agent, among
those tested by the ITP, that significantly increases both male and female
lifespan. Compared with rapamycin, ACA produces larger median
effects and similar 90th percentile effects in males; effects in females are
much less than produced by rapamycin (Harrison et al., 2009; Miller
et al., 2011). The ACA result draws attention to the possibility that
transient fluctuations in plasma glucose, thought to be blunted in ACA-
treated mice, may play a role in aging and in cancer biology.
Comparisons of ACA to various food restriction protocols are likely to
be quite informative: both ACA and DR lead to longevity, some change
in body mass (much more severe in DR mice), and alterations in glucose/
insulin physiology, but the two protocols differ in fasting glucose,
stimulation of spontaneous activity and perhaps other CNS responses,
post-prandial glucose pulse height, and in the sexual specificity of the
lifespan response. Our data show that drugs can lead to dramatically
different effects on lifespan in the two sexes, with ACA, NDGA, and
(perhaps) EST showing benefits in males, and rapamycin showing
consistently stronger effects in females (Harrison et al., 2009; Miller
et al., 2011, and unpublished results). The hints of benefits from MB
suggest that MB might lead to lifespan and anti-aging benefits using
other doses or alternate dosage schedules or both. More generally, the
growing arsenal of drugs that extend lifespan, perhaps by modulation of
aging, cancer, or both, will complement work performed using mutant
stocks and dietary interventions to delineate the factors that control
aging rate in mammals and link aging to multiple forms of illness.
Experimental procedures
Mouse production, maintenance, and estimation of lifespan
UM-HET3 mice were produced at each of the three test sites as
previously described (Strong et al., 2008; Harrison et al., 2009; Miller
et al., 2011), where environmental conditions are presented in detail.
The dams of the test mice were CByB6F1/J, JAX stock #100009 (dams,
BALB/cByJ; sires, C57BL/6J). The sires of the test mice were C3D2F1/J,
JAX stock #100004 (dams, C3H/HeJ; sires, DBA/2J). In each site,
breeding mice were fed LabDiet 5008 mouse chow (PMI Nutritional
International, Bentwood, MO, USA). As soon as mice were weaned, they
were fed LabDiet 5LG6 from the same source.
Details of the methods used for health monitoring were provided
previously (Strong et al., 2008; Harrison et al., 2009; Miller et al., 2011).
In brief, each of the three colonies was evaluated four times each year
for infectious agents. All such surveillance tests were negative for
pathogens at all three sites throughout the entire study period.
Removal of mice from the longevity population
Mice were removed from the study because of fighting or accidental
death (e.g., during chip implantation) or chip failure, or because they
were used for another experimental purpose, such as testing immune
responses. For survival analyses, all such mice were treated as alive at the
date of their removal from the protocol and lost to follow-up thereafter.
These mice were not included in calculations of median longevity.
Overall, 3–5% of the mice were removed from the longevity populations
reported here, with no significant site differences, except that about
20% of female controls were removed at TJL to be used for a separate
investigation.
Estimation of age at death (lifespan)
At UM and UT, mice were examined daily for signs of ill health from the
time they were set up in the experiment. At JAX, once mice were
marked as ill, they were examined daily for signs of ill health. Mice were
euthanized for humane reasons if so severely moribund that they were
considered, by an experienced technician, unlikely to survive for more
than an additional 48 h. A mouse was considered severely moribund if it
exhibited more than one of the following clinical signs: (i) severe
lethargy, as indicated by reluctance to move when gently prodded with a
forceps; (ii) inability to eat or to drink, for example due to a severe
balance or gait disturbance; (iii) rapid weight loss over a period of
1 week or more; or (iv) a severely ulcerated or bleeding tumor. The age
at which a moribund mouse was euthanized was taken as the best
available estimate of its natural lifespan. Mice found dead were also
noted at each daily inspection.
Control and experimental diets
TestDiet, Inc., a division of Purina Mills (Richmond, IN, USA), prepared
batches of LabDiet 5LG6 food containing each of the test substances,
as well as control diet batches, at intervals of approximately 4 months,
and shipped each batch of food at the same time to each of the three
test sites. Acarbose was purchased from Spectrum Chemical Mfg. Corp.,
Gardena, CA. It was mixed at a concentration of 1000 mg of ACA per
kilogram of diet (1000 ppm); mice were fed continuously from
4 months of age. 17 a-estradiol (EST) was purchased from Steraloids,
Inc. (Newport, RI, USA) and mixed at a dose of 4.8 mg kg1 of diet
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(4.8 ppm); mice were fed continuously from 10 months of age.
Methylene blue (MB) was purchased as methylene blue hydrate (Cat #
66720) from Sigma-Aldrich (St Louis, MO) and mixed at 28 mg kg1 of
diet (28 ppm); mice were fed continuously from 4 months of age.
Nordihydroguaiaretic acid (NDGA) was purchased from Cayman Chem-
icals (Ann Arbor, MI, USA) and was mixed at concentrations of 800,
2500, or 5000 mg kg1 of diet (800, 2500, 5000 ppm); mice were fed
continuously from 6 months of age. Lifespan data for NDGA are not
complete because these studies were started a year later than the others
reported. NDGA treatment was in Cohort 2010 mice, while ACA, EST,
and MB treatments were included in Cohort 2009.
Measurement of NDGA
NDGA was quantified in mouse blood using HPLC with electrochemical
detection. Briefly, 100 lL of calibrators, controls, and unknown samples
were mixed with 0.9 mL of a 50% ACN/25% IPA/25% EtOH/0.1%
ascorbic acid solution. The samples were vortexed vigorously and then
centrifuged at 3200 g for 20 min. Supernatants were transferred to
glass test tubes and dried to residue under a gentle stream of nitrogen.
The residues were redissolved in 100 lL of mobile phase and then
filtered using a microfilterfuge tube. Then, 50 lL of the final samples
was injected into the HPLC-EC system. The peak area of NDGA was
compared against a linear regression of peak areas of calibrators at
concentrations of 0, 10, 50, 100, 500, and 1000 ng mL1 to quantify
NDGA in the blood samples. NDGA concentration in blood was reported
in ng mL1.
The HPLC-electrochemical system consisted of an Alltima C18 column
(4.6 9 150 mm, 3 micrometer) heated to 36 °C, ESA Coulochem II
Detector with 5011 detector cell, Waters 717 autosampler, and a Waters
515 HPLC pump. The mobile phase was 50% MeOH, 49.5% Milli-Q
water, 0.1 mM EDTA, and 0.5% phosphoric acid (pH 2.5). The flow rate
of the mobile phase was 0.75 mL min1, and the detector settings were
E1: +450 mV, R1: 100 nA, E2: 350 mV, R2: 100 nA, Guard Cell:
+300 mV.
Statistical methods
Each mouse originally entered into the study was, at the time of analysis,
considered to be in one of two categories: either dead (from natural
causes) or censored. Mice were censored at the age when they were no
longer subjected to the mortality risks typical of unmanipulated mice. In
some cases, this was because the mouse was removed because of
fighting; in other cases, mice died as the result of an accident (e.g.,
death when anesthetized for implantation of a radio-emitting chip). In
still other cases, mice were considered censored on the day in which they
received an experimental treatment (such as blood sampling or tests of
immune response) to which the control mice were not exposed. Kaplan–
Meier analysis and log-rank comparisons among groups considered
censored mice to be lost from follow-up on the day at which they were
removed from the longevity protocol. There were no mice remaining
alive in the ACA, EST, and MB groups at the time of the analyses
reported here. Only about 70% of the mice given NDGA and controls
had died when these analyses were performed, so only median data are
reported.
Unless stated otherwise, all significance tests about survival effects are
based upon the two-tailed log-rank test at P < 0.05, stratified by test
site, with censored mice included up until their date of removal from the
longevity population. Other statistical tests are described in the text; all
P-values are two-tailed and reported without adjustment for multiple
comparisons. Statistical claims related to maximum lifespan are based on
the procedure of Wang et al. (2004), which uses the Fisher exact test to
compare the proportions of surviving mice, in Control and Test groups,
at the age corresponding to the 90th percentile for survival in the joint
distribution of the Control and Test groups together. For the pooled data
sets, surviving mice were enumerated at the 90th percentile age for each
site separately, and these counts were combined for the overall Fisher
exact test.
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Fig. S1 ACA treatment: Site-specific survival curves for UM-HET3 controls (A,
B) and ACA-fed male (C) and female (D) mice.
Fig. S2 ACA, EST and MB treatment: weights for UM-HET3 controls and
males (A–C) and females (D–F) at TJL (A,D), UM (B,E), and UT (C,F).
Fig. S3 EST treatment: Survival for UM-HET3 control females pooled across
sites (A) and EST-treated females at TJL (B), UM (C), and UT (D).
Fig. S4 NDGA treatment: Interim survival for UM-HET3 controls and NDGA-
treated males at TJL (A), UM (B), and UT (C), and UM-HET3 controls and
NDGA-treated females at TJL (D), UM (E), and UT (F).
Fig. S5 NDGA levels in plasma of UM-HET3 controls and males treated with
high (5000 ppm), middle (2500 ppm), or low dose (9800 ppm) of NDGA in
the diet (A), and UM-HET3 controls and females treated with high dose of
NDGA (B).
Fig. S6 NDGA treatment: Body weights for UM-HET3 controls and males
treated with high, middle, and low dose of NDGA (A), and for UM-HET3
controls and females treated with high dose of NDGA (B).
Fig. S7 MB treatment: Survival curves for UM-HET3 controls and mice fed
MB in the diet for males at TJL (A), UM (B), and UT (C), and for females at TJL
(D), UM (E), and UT (F).
Table S1 ACA and EST treatment: Inferred causes of death in aging UM-
HET3 controls and ACA- and EST-treated males and females
Table S2 Survival in UM-HET3 control and male mice that were treated with
ACA, EST, and MB in the diet and that lived at least 600 days
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